W Henry Boom

List of Publications by Year in descending order

68 papers	6,077 citations	94381 37 h-index	95218 68 g-index
70 all docs	70 docs citations	70 times ranked	6456 citing authors

#	Article	IF	Citations
1	A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet, The, 2016, 387, 2312-2322.	6.3	678
2	Toll-Like Receptor 2-Dependent Inhibition of Macrophage Class II MHC Expression and Antigen Processing by 19-kDa Lipoprotein of<i>Mycobacterium tuberculosis</i>. Journal of Immunology, 2001, 167, 910-918.	0.4	391
3	Regulation of antigen presentation by Mycobacterium tuberculosis: a role for Toll-like receptors. Nature Reviews Microbiology, 2010, 8, 296-307.	13.6	349
4	Mycobacterium tuberculosis lineage 4 comprises globally distributed and geographically restricted sublineages. Nature Genetics, 2016, 48, 1535-1543.	9.4	326
5	Immunological mechanisms of human resistance to persistent Mycobacterium tuberculosis infection. Nature Reviews Immunology, 2018, 18, 575-589.	10.6	241
6	<i>Mycobacterium tuberculosis</i>LprG (<i>Rv1411c</i>): A Novel TLR-2 Ligand That Inhibits Human Macrophage Class II MHC Antigen Processing. Journal of Immunology, 2004, 173, 2660-2668.	0.4	231
7	Inhibition of IFN-Î³-Induced Class II Transactivator Expression by a 19-kDa Lipoprotein from<i>Mycobacterium tuberculosis</i>: A Potential Mechanism for Immune Evasion. Journal of Immunology, 2003, 171, 175-184.	0.4	226
8	Four-Gene Pan-African Blood Signature Predicts Progression to Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1198-1208.	2.5	217
9	<i>Mycobacterium tuberculosis</i> LprA Is a Lipoprotein Agonist of TLR2 That Regulates Innate Immunity and APC Function. Journal of Immunology, 2006, 177, 422-429.	0.4	203
10	<i>Mycobacterium tuberculosis</i>19-kDa Lipoprotein Inhibits IFN-Î³-Induced Chromatin Remodeling of<i>MHC2TA</i>by TLR2 and MAPK Signaling. Journal of Immunology, 2006, 176, 4323-4330.	0.4	198
11	Sequential inflammatory processes define human progression from M. tuberculosis infection to tuberculosis disease. PLoS Pathogens, 2017, 13, e1006687.	2.1	193
12	IFN-Î³-independent immune markers of Mycobacterium tuberculosis exposure. Nature Medicine, 2019, 25, 977-987.	15.2	186
13	Prolonged Toll-Like Receptor Signaling by Mycobacterium tuberculosis and Its 19-Kilodalton Lipoprotein Inhibits Gamma Interferon-Induced Regulation of Selected Genes in Macrophages. Infection and Immunity, 2004, 72, 6603-6614.	1.0	150
14	TLR2 and its co-receptors determine responses of macrophages and dendritic cells to lipoproteins of Mycobacterium tuberculosis. Cellular Immunology, 2009, 258, 29-37.	1.4	137
15	Mycobacterium tuberculosis lipoprotein LprG (Rv1411c) binds triacylated glycolipid agonists of Toll-like receptor 2. Nature Structural and Molecular Biology, 2010, 17, 1088-1095.	3.6	122
16	Processing of Mycobacterium tuberculosis Antigen 85B Involves Intraphagosomal Formation of Peptideâ€"Major Histocompatibility Complex II Complexes and Is Inhibited by Live Bacilli that Decrease Phagosome Maturation. Journal of Experimental Medicine, 2001, 194, 1421-1432.	4.2	121
17	Bacillus Calmetteâ€"GuÃ©rin (BCG) Revaccination of Adults with Latent <i>Mycobacterium tuberculosis</i> Infection Induces Long-Lived BCG-Reactive NK Cell Responses. Journal of Immunology, 2016, 197, 1100-1110.	0.4	121
18	Longitudinal Changes in CD4+ T-Cell Memory Responses Induced by BCG Vaccination of Newborns. Journal of Infectious Diseases, 2013, 207, 1084-1094.	1.9	120

#	Article	IF	Citations
19	Bacterial Factors That Predict Relapse after Tuberculosis Therapy. New England Journal of Medicine, 2018, 379, 823-833.	13.9	114
20	Bacterial Membrane Vesicles Mediate the Release of <i>Mycobacterium tuberculosis</i> Lipoglycans and Lipoproteins from Infected Macrophages. Journal of Immunology, 2015, 195, 1044-1053.	0.4	107
21	<i>Mycobacterium tuberculosis</i>Synergizes with ATP To Induce Release of Microvesicles and Exosomes Containing Major Histocompatibility Complex Class II Molecules Capable of Antigen Presentation. Infection and Immunity, 2010, 78, 5116-5125.	1.0	102
22	Inhibition of Major Histocompatibility Complex II Expression and Antigen Processing in Murine Alveolar Macrophages by Mycobacterium bovis BCG and the 19-Kilodalton Mycobacterial Lipoprotein. Infection and Immunity, 2004, 72, 2101-2110.	1.0	100
23	Toll-Like Receptor 2-Dependent Extracellular Signal-Regulated Kinase Signaling in Mycobacterium tuberculosis-Infected Macrophages Drives Anti-Inflammatory Responses and Inhibits Th1 Polarization of Responding T Cells. Infection and Immunity, 2015, 83, 2242-2254.	1.0	94
24	<i>Mycobacterium tuberculosis</i> Lipoproteins Directly Regulate Human Memory CD4 ⁺ T Cell Activation via Toll-Like Receptors 1 and 2. Infection and Immunity, 2011, 79, 663-673.	1.0	69
25	Resistance and Susceptibility to Mycobacterium tuberculosis Infection and Disease in Tuberculosis Households in Kampala, Uganda. American Journal of Epidemiology, 2018, 187, 1477-1489.	1.6	69
26	The knowns and unknowns of latent Mycobacterium tuberculosis infection. Journal of Clinical Investigation, 2021, 131, .	3.9	67
27	CCAAT/Enhancer-Binding Protein Î² and Î´ Binding to CIITA Promoters Is Associated with the Inhibition of CIITA Expression in Response to<i>Mycobacterium tuberculosis</i>19-kDa Lipoprotein. Journal of Immunology, 2007, 179, 6910-6918.	0.4	66
28	<i>Mycobacterium tuberculosis</i> Membrane Vesicles Inhibit T Cell Activation. Journal of Immunology, 2017, 198, 2028-2037.	0.4	66
29	Regulation of mammalian siderophore 2,5-DHBA in the innate immune response to infection. Journal of Experimental Medicine, 2014, 211, 1197-1213.	4.2	64
30	Transcriptional networks are associated with resistance to Mycobacterium tuberculosis infection. PLoS ONE, 2017, 12, e0175844.	1.1	64
31	Mycobacterium tuberculosis ManLAM inhibits T-cell-receptor signaling by interference with ZAP-70, Lck and LAT phosphorylation. Cellular Immunology, 2012, 275, 98-105.	1.4	58
32	MR1-Independent Activation of Human Mucosal-Associated Invariant T Cells by Mycobacteria. Journal of Immunology, 2019, 203, 2917-2927.	0.4	55
33	Mycobacterium bovis BCG decreases MHC-II expression in vivo on murine lung macrophages and dendritic cells during aerosol infection. Cellular Immunology, 2009, 254, 94-104.	1.4	53
34	Polymorphisms in TICAM2 and IL1B are associated with TB. Genes and Immunity, 2015, 16, 127-133.	2.2	49
35	Analysis of Host Responses to Mycobacterium tuberculosis Antigens in a Multi-Site Study of Subjects with Different TB and HIV Infection States in Sub-Saharan Africa. PLoS ONE, 2013, 8, e74080.	1.1	48
36	Phagocytic antigen processing and effects of microbial products on antigen processing and T-cell responses. Immunological Reviews, 1999, 168, 217-239.	2.8	47

#	Article	IF	Citations
37	<i>Mycobacterium tuberculosis</i>Cell Wall Glycolipids Directly Inhibit CD4⁺T-Cell Activation by Interfering with Proximal T-Cell-Receptor Signaling. Infection and Immunity, 2009, 77, 4574-4583.	1.0	46
38	Long-term Stability of Resistance to Latent Mycobacterium tuberculosis Infection in Highly Exposed Tuberculosis Household Contacts in Kampala, Uganda. Clinical Infectious Diseases, 2019, 68, 1705-1712.	2.9	46
39	Interaction between host genes and Mycobacterium tuberculosis lineage can affect tuberculosis severity: Evidence for coevolution?. PLoS Genetics, 2020, 16, e1008728.	1.5	40
40	Effect of Isoniazid Therapy for Latent TB Infection on QuantiFERON-TB Gold In-Tube Responses in Adults With Positive Tuberculin Skin Test Results in a High TB Incidence Area. Chest, 2014, 145, 612-617.	0.4	37
41	A side-by-side comparison of T cell reactivity to fifty-nine Mycobacterium tuberculosis antigens in diverse populations from five continents. Tuberculosis, 2015, 95, 713-721.	0.8	35
42	Mannose-Capped Lipoarabinomannan from <i>Mycobacterium tuberculosis</i> Induces CD4+ T Cell Anergy via GRAIL. Journal of Immunology, 2016, 196, 691-702.	0.4	35
43	Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults. Vaccine, 2014, 32, 3982-3988.	1.7	33
44	Toll like Receptor 2 engagement on CD4⁺ T cells promotes TH9 differentiation and function. European Journal of Immunology, 2017, 47, 1513-1524.	1.6	31
45	Effectiveness of WHO's pragmatic screening algorithm for child contacts of tuberculosis cases in resource-constrained settings: a prospective cohort study in Uganda. Lancet Respiratory Medicine,the, 2018, 6, 276-286.	5.2	23
46	Insights into the <scp>l</scp> , <scp>d</scp> -Transpeptidases and <scp>d</scp> , <scp>d</scp> -Carboxypeptidase of Mycobacterium abscessus: Ceftaroline, Imipenem, and Novel Diazabicyclooctane Inhibitors. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	22
47	Early Bactericidal Activity of AZD5847 in Patients with Pulmonary Tuberculosis. Antimicrobial Agents and Chemotherapy, 2016, 60, 6591-6599.	1.4	19
48	Effects of BCG vaccination on donor unrestricted T cells in two prospective cohort studies. EBioMedicine, 2022, 76, 103839.	2.7	19
49	Activity of nitazoxanide and tizoxanide against Mycobacterium tuberculosis inÂvitro and in whole blood culture. Tuberculosis, 2016, 98, 92-96.	0.8	17
50	Proteomic and bioinformatics profile of paired human alveolar macrophages and peripheral blood monocytes. Proteomics, 2015, 15, 3797-3805.	1.3	15
51	â€œOne-Two Punchâ€• Synergistic ÃŸ-Lactam Combinations for<i>Mycobacterium abscessus</i>and Target Redundancy in the Inhibition of Peptidoglycan Synthesis Enzymes. Clinical Infectious Diseases, 2021, 73, 1532-1536.	2.9	15
52	Monocyte metabolic transcriptional programs associate with resistance to tuberculin skin test/interferon-Î³ release assay conversion. Journal of Clinical Investigation, 2021, 131, .	3.9	13
53	Tuberculin Skin Test Reversion following Isoniazid Preventive Therapy Reflects Diversity of Immune Response to Primary Mycobacterium tuberculosis Infection. PLoS ONE, 2014, 9, e96613.	1.1	13
54	Inhibiting Mycobacterium abscessus Cell Wall Synthesis: Using a Novel Diazabicyclooctane Î²-Lactamase Inhibitor To Augment Î²-Lactam Action. MBio, 2022, 13, e0352921.	1.8	13

#	Article	IF	Citations
55	HDAC3 inhibitor RGFP966 controls bacterial growth and modulates macrophage signaling during Mycobacterium tuberculosis infection. Tuberculosis, 2021, 127, 102062.	0.8	11
56	Comparison of MGIT and Myco/F Lytic Liquid-Based Blood Culture Systems for Recovery of Mycobacterium tuberculosis from Pleural Fluid. Journal of Clinical Microbiology, 2015, 53, 1391-1394.	1.8	10
57	Proteomics and Network Analyses Reveal Inhibition of Aktâ€mTOR Signaling in CD4⁺ T Cells by <i>Mycobacterium tuberculosis</i> Mannoseâ€Capped Lipoarabinomannan. Proteomics, 2017, 17, 1700233.	1.3	10
58	Genetic variability and consequence of Mycobacterium tuberculosis lineage 3 in Kampala-Uganda. PLoS ONE, 2019, 14, e0221644.	1.1	10
59	Incubation time of Mycobacterium tuberculosis complex sputum cultures in BACTEC MGIT 960: 4weeks of negative culture is enough for physicians to consider alternative diagnoses. Diagnostic Microbiology and Infectious Disease, 2015, 83, 162-164.	0.8	9
60	Elucidation of a Human Urine Metabolite as a Seryl-Leucine Glycopeptide and as a Biomarker of Effective Anti-Tuberculosis Therapy. ACS Infectious Diseases, 2019, 5, 353-364.	1.8	9
61	Resistance to TST/IGRA conversion in Uganda: Heritability and Genome-Wide Association Study. EBioMedicine, 2021, 74, 103727.	2.7	9
62	Monocyte Transcriptional Responses to Mycobacterium tuberculosis Associate with Resistance to Tuberculin Skin Test and Interferon Gamma Release Assay Conversion. MSphere, 2022, 7, .	1.3	8
63	How we determined the most reliable solid medium for studying treatment of tuberculosis. Tuberculosis, 2014, 94, 317-322.	0.8	5
64	A single-nucleotide-polymorphism real-time PCR assay for genotyping of Mycobacterium tuberculosis complex in peri-urban Kampala. BMC Infectious Diseases, 2015, 15, 396.	1.3	5
65	Importance of Study Design and Phenotype Definition in Ongoing Studies of Resistance to Latent Mycobacterium tuberculosis Infection. Journal of Infectious Diseases, 2020, 221, 1025-1026.	1.9	5
66	Interaction between M. tuberculosis Lineage and Human Genetic Variants Reveals Novel Pathway Associations with Severity of TB. Pathogens, 2021, 10, 1487.	1.2	5
67	The Pup-Proteasome System Protects Mycobacteria from Antimicrobial Antifolates. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	3
68	Methylome-wide Analysis Reveals Epigenetic Marks Associated With Resistance to Tuberculosis in Human Immunodeficiency Virusâ€“Infected Individuals From East Africa. Journal of Infectious Diseases, 2021, 224, 695-704.	1.9	1